Page 50 - ATHM26_4

26. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin
AUTHOR DISCLOSURE STATEMENT and paclitaxel neuropathy with glutamate. J Neurooncol. 1999;41(2):107-116.
No financial relationships exist to be disclosed. 27. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental
vincristine neuropathy. J Pharmacol Exp Ther. 1996;279(1):410-415.
28. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch
REFERENCES CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced
1. Cavaletti G, Zanna C. Current status and future prospects for the treatment of peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol (R Coll
chemotherapy-induced peripheral neurotoxicity. Eur J Cancer. 2002;38(14):1832- Radiol). 2005;17(4):271-276.
1837. 29. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced
2. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7(5):1192-1197.
Syst. 2008;13(1):27-46. 30. Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing
3. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist.
Rev Neurol. 2010;6(12):657-666. 2007;12(3):312-319.
4. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A 31. Sands S. Glutamine for the treatment of vincristine-induced neuropathy in
comprehensive survey. Cancer Treat Rev. 2014;40(7):872-882. children and adolescents with cancer. Support Care Cancer. 2017;25(3):701-708.
5. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: 32. Sun WN, Su JW, Shen ZP, Hsu HT. Effect of oral glutamine on chemotherapy-
Management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7 (suppl induced peripheral neuropathy in cancer patients: An evidence-based appraisal.
5):S1-S26. Hu Li Za Zhi. 2018;65(1):61-69.
6. Shah A, Hoffman EM, Mauermann ML, et al. Incidence and disease burden of 33. Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl-L-carnitine: From a biological
chemotherapy-induced peripheral neuropathy in a population-based cohort. J curiosity to a drug for the peripheral nervous system and beyond. Expert Rev
Neurol Neurosurg Psychiatry. 2018;89(6):636-641. Neurother. 2013;13(8):925-936.
7. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral 34. Winter BK, Fiskum G, Gallo LL. Effects of L-carnitine on serum triglyceride and
neurotoxicity assessment: a critical revision of the currently available tools. Eur J cytokine levels in rat models of cachexia and septic shock. Br J Cancer.
Cancer. 2010;46(3):479-494. 1995;72(5):1173-1179.
8. Hershman DL, Lacchetti C, Loprinzi CL. Prevention and management of 35. Liu Y, Rosenthal RE, Starke-Reed P, Fiskum G. Inhibition of post–cardiac arrest
chemotherapy-induced peripheral neuropathy in survivors of adult cancers: brain protein oxidation by acetyl-L-carnitine. Free Radic Biol Med. 1993;15(6):667-
American Society of Clinical Oncology Clinical Practice Guideline Summary. J 670.
Oncol Pract. 2014;10(6):e421-e424. 36. van Dam DG, Beijers AJ, Vreugdenhil G. Acetyl-L-carnitine undervalued in the
9. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of treatment of chemotherapy-induced peripheral neuropathy? Acta Oncol.
chemotherapy-induced peripheral neuropathy: A systematic review and meta- 2016;55(12):1495-1497.
analysis. Pain. 2014;155(12):2461-2470. 37. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological
10. Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.
effects, pathophysiological mechanisms, and risk factors of chemotherapy- Eur J Cancer. 2005;41(12):1746-1750.
induced peripheral neuropathies: A comprehensive literature review. Front 38. Sun Y, Shu Y, Liu B, et al. A prospective study to evaluate the efficacy and safety of
Pharmacol. 2017;24;8:86. oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral
11. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for neuropathy. Exp Ther Med. 2016;12(6):4017-4024.
chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3-9. 39. Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-
12. Argyriou AA, Bruna J, Genazzani AA, Cavaletti G. Chemotherapy-induced controlled trial of acetyl-L-carnitine for the prevention of taxane-induced
peripheral neurotoxicity: Management informed by pharmacogenetics. Nat Rev neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol.
Neurol. 2017;13(8):492-504. 2013;31(20):2627-2633.
13. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent developments of 40. Hershman DL, Unger JM, Crew KD, et al. Two-year trends of taxane-induced
novel pharmacologic therapeutics for prevention of chemotherapy-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG
peripheral neuropathy. Clin Cancer Res. 2019;1(1):1. S0715). J Natl Cancer Inst. 2018;110(6):669-676.
14. Huaping Huang. Vitamin E does not decrease the incidence of chemotherapy- 41. Callander N, Markovina S, Eickhoff J, et al. Acetyl-L-carnitine (ALCAR) for the
induced peripheral neuropathy: A meta-analysis. Contemp Oncol (Pozn). prevention of chemotherapy-induced peripheral neuropathy in patients with
2016;20(3):237-241. relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin
15. Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin and low-dose dexamethasone: A study from the Wisconsin Oncology Network.
neuropathy: A randomized, placebo-controlled trial. Neurology. 2010;74(9):762- Cancer Chemother Pharmacol. 2014;74(4): 875-882.
766. 42. Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial
16. Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating damage and neurotoxicity in experimental chemotherapy neuropathy. Exp
the efficacy and safety of vitamin E supplementation for protection against Neurol. 2008;214(2):276-284.
cisplatin-induced peripheral neuropathy: Final results. Support Care Cancer. 43. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic
2006;14(11):1134-1140. diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A meta-analysis.
17. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against Diabet Med. 2004;21(2):114-121.
chemotherapy-induced neuropathy: A randomized controlled trial. Neurology. 44. Guo Y, Jones D, Palmer JL, et al. Oral alpha-lipoic acid to prevent chemotherapy-
2005;64(1):26-31. induced peripheral neuropathy: a randomized, double-blind, placebo-controlled
18. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E trial. Support Care Cancer. 2014;22(5):1223-1231.
supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 45. Cho YS, Lee J, Lee TH, et al. alpha-Lipoic acid inhibits airway inflammation and
2003;21(5):927-931. hyperresponsiveness in a mouse model of asthma. J Allergy Clin Immunol.
19. Huaping Huang. Vitamin E does not decrease the incidence of chemotherapy- 2004;114(2):429-435.
induced peripheral neuropathy: a meta-analysis. Contemp Oncol (Pozn). 46. Lin YC, Lai YS, Chou TC. The protective effect of alpha-lipoic acid in
2016;20(3):237-241. lipopolysaccharide-induced acute lung injury is mediated by heme oxygenase-1.
20. Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the Evid Based Complement Alternat Med. 2013;2013:590363.
prevention of chemotherapy-induced peripheral neuropathy: Results of a 47. Zheng ZG CY, Hong DH, Lin YB, Zheng WH. Efficacy of α-lipoic acid combined
randomized phase III clinical trial. Support Care Cancer. 2011;19:1769-1777. with mecobalamin for chemotherapy-induced peripheral neuropathy. Evaluation
21. Schloss J, Colosimo M. B Vitamin Complex and chemotherapy-induced and Analysis of Drug-Use in Hospitals of China. 2015;15(6):729-731.
peripheral neuropathy. Curr Oncol Rep. 2017;19(12):76. 48. Balendiran GK, Dabur R, Fraser D. The role of glutathione in cancer. Cell Biochem
22. Kopruszinski CM, Reis RC, Chichorro JG. B vitamins relieve neuropathic pain Funct. 2004;22(6):343-352.
behaviors induced by infraorbital nerve constriction in rats. Life Sci. 2012;91(23- 49. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective
24):1187-1195. effect of reduced glutathione on cisplatin-based chemotherapy in advanced
23. Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, gastric cancer: A randomized double-blind placebo-controlled trial. J Clin Oncol.
placebo-controlled trial assessing the efficacy of an oral B group vitamin in 1995;13(1):26-32.
preventing the development of chemotherapy-induced peripheral neuropathy 50. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced
(CIPN). Support Care Cancer. 2017;25(1):195-204. glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A
24. Gwag BJ, Sessler FM, Robine V, Springer JE. Endogenous glutamate levels regulate randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20(16):3478-
nerve growth factor mRNA expression in the rat dentate gyrus. Mol Cells. 3483.
1997;7:425-430. 51. Traverso N, Ricciarelli R, Nitti M, et al. Role of glutathione in cancer progression
25. Sands S, Ladas EJ, Kelly KM, et al. Glutamine for the treatment of vincristine- and chemoresistance. Oxid Med Cell Longev. 2013;2013:972913.
induced neuropathy in children and adolescents with cancer. Support Care 52. Hamilton D, Batist G. Glutathione analogues in cancer treatment. Curr Oncol Rep.
Cancer. 2017;25(3):701-708. 2004;6(2):116-122.

48 ALTERNATIVE THERAPIES, JUL/AUG 2020 VOL. 26 NO. 4 Liu—Complementary Nutritional Supplements and Chemotherapy-induced